On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


RYAH Group Committed to Advancing Telehealth in HIPAA-Compliant Environment

  • Telehealth sector going through explosive growth; patients’ data protection remains key challenge
  • Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients’ data security, privacy likely to tighten as pandemic abates
  • RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting

Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements.

With patients needing more access to health care, and providers and payers looking to reduce health-care costs, the use of telehealth solutions is exploding. More and more medical staff and patients alike are embracing digital healthcare options as a replacement for in-person care. Although the pandemic fuels the recent surge, the overall growth is not likely to stop once the pandemic tails off. For example, the global telemedicine market is expected to exceed $130.5 billion by 2025, with the U.S. telemedicine market expected to surpass $64.1 billion by 2025 (https://ibn.fm/AVY0p).

The technologies that power telemedicine growth are big data analytics and cloud computing. The enormous amount of data generated by devices such as smartphones, monitoring technologies, wearables and online video conferencing has opened up a world of opportunities that allows information sharing and superior analytics. Only two barriers impede the widespread adoption of big data and cloud computing in telemedicine: data privacy and security. If these critical aspects are addressed, the power of the novel technology can be harnessed to its true potential (https://ibn.fm/YRVm3).

Both patients and medical professionals are becoming accustomed to communicating through electronic devices. Although telehealth brings immense benefits, especially during the pandemic, it creates risks that must be addressed. For example, it opens up opportunities for patients’ information to fall into the wrong hands, either by accidental or malicious intent. Transmitting protected health information through unencrypted, unsecured platforms may expose protected health information.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is the U.S. legislation designed to ensure that medical providers provide data privacy and security provisions for safeguarding their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain as the pandemic subsides. Therefore, it is critical for health-care providers to use secure, HIPAA-compliant digital infrastructure to protect both themselves and patients at risk.

Unified data management is critical to ensuring that the right users have access to the right health-care data at the right time and in the right format. It allows health-care providers to have meaningful use of their data assets. Integrated data management, along with a formal data governance program, ensures data quality and trust in the data integrity.

As a company focused on the use of health devices, RYAH and its business model is founded on data and data management. RYAH leverages HIPAA-compliant medical data, fueling complex artificial intelligence algorithms to empower personalized treatment plans based on collective information.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.